Latest Oncology News

Adjuvant Aumolertinib Boosts DFS in Stage II-IIIB, EGFR-Mutated NSCLC

April 30th 2025

Chris Ryan

Adjuvant aumolertinib improved disease-free survival in complete resected stage II to IIIB non–small cell lung cancer harboring EGFR mutations.

Adjuvant Trifluridine/Tipiracil Benefit is Limited to Select Subgroups in MRD+ CRC

April 30th 2025

Jax DiEugenio

Trifluridine/tipiracil showed a favorable safety profile and numerically improved DFS vs placebo in MRD-positive CRC.

Adagrasib Yields Early Efficacy in STK11- and KRAS G12C–Mutant NSCLC

April 30th 2025

Jordyn Sava

First-line adagrasib monotherapy demonstrated preliminary efficacy and tolerability in patients with SK11- and KRAS G12C–mutant NSCLC.

Subgroup Analysis Shows No Key Differences Between High-Grade Recurrence, Cancer Progression Outcomes in BCG-Unresponsive NMIBC

April 30th 2025

Ashley Chan

Among 3 subgroups of patients with BCG-unresponsive NMIBC, no significant clinical differences were identified regarding rates of high-grade recurrence.

Neoadjuvant Botensilimab Plus Balstilimab Is Active, Safe Regardless of Mismatch Repair Status in Solid Tumors

April 30th 2025

Caroline Seymour

Botensilimab and balstilimab proved active and safe as neoadjuvant therapy in patients with mismatch repair–deficient and –proficient solid tumors.

Latest Oncology Videos

Dr Randall on the Use of Osteosarcoma Spheroid Models to Streamline Preclinical Therapeutic Development

Timing and Candidacy for AlloHSCT in MDS

Dr Kuerer on Selective Surgery Omission After Response to Neoadjuvant Therapy in Invasive Breast Cancer

Presenting the Treatment Options in EGFR-Mutant NSCLC: Weighing the Data and Incorporating the Patient Perspective

The Evolution of ctDNA Assays in CRC

Dr Chan on Unmet Needs Addressed by the FDA Approval of Cabozantinib for pNET and epNET

Dr Shadman on the Utility of a Meta Analysis of BTK Inhibitors in R/R CLL

Dr Chase on Considering Patient Preferences for Treatment Planning in Gynecologic Oncology

Dr Petrylak on the Importance of Early Detection to Minimize Treatment Intensity in Testicular Cancer

Dr Moschos on Treatment Strategies With Adoptive T-Cell Therapy in Melanoma

Dr Simpkins on the Predictive Utility of Cyclin E1 for Azenosertib Response in Ovarian Cancer

Dr Pimenta on Adipogenesis Defects Characteristic of Dedifferentiated Liposarcoma

Dr Siegel on the Evaluation of Mezigdomide for R/R Myeloma

Lung Cancer Experts Highlight the Significance and Limitations of ADCs

Clinical Insights Into Treatment Approach for Metastatic HER+ mBC Patient Case

How ctDNA Is Informing Ongoing Trials in CRC

Talking to Patients With CRC About ctDNA

Implications From the BESPOKE CRC Study Evaluating ctDNA in Stage II-III CRC

Clinical Scenario I: 52-year-old Woman With Recurrent Metastatic HER2+ Breast Cancer

AlloHSCT in AML: When, Why, and for Whom?

CIRCULATE-Japan: Diving Into ctDNA and DFS Data in Stage II-IV CRC

Why ctDNA Remains a Focal Point in CRC Research

A Focus on the Role of Patient Navigators in the Diagnosis and Management of Early-Stage NSCLC

All Oncology News

Fox Chase Cancer Center’s Dr. Jonathan Chernoff Elected to Association of American Physicians

April 30th 2025

Fox Chase Cancer Center

Jonathan Chernoff, MD, PhD, Cancer Center Director of Fox Chase Cancer Center, was recently elected to the Association of American Physicians (AAP).

CHMP Recommends Approval of At-Home, Subcutaneous Trastuzumab/Pertuzumab in HER2+ Breast Cancer

April 30th 2025

Jax DiEugenio

The EMA’s CHMP has recommended at-home administration of pertuzumab, trastuzumab and hyaluronidase combination therapy for HER2+ breast cancer.

Advancing Brain Metastases Research and Mentorship in Breast Oncology: With D. Ross Camidge, MD, PhD; Nancy U. Lin, MD

April 30th 2025

D. Ross Camidge, MD, PhD

Drs Camidge and Lin discussed Dr Lin's work with brain metastases and her role in developing targeted therapies for breast cancer.

FDA Grants Fast Track Designation to INX-315 in CCNE1-Amplified, Platinum-Resistant Ovarian Cancer

April 30th 2025

Courtney Flaherty

INX-315 has received FDA fast track designation for the treatment of patients with CCNE1-amplified, platinum-resistant or refractory ovarian cancer.

Early Ruxolitinib Initiation Increases Spleen Response Rates in Myelofibrosis

April 30th 2025

Ashling Wahner

Patients with myelofibrosis who initiated ruxolitinib within 2 years of diagnosis achieved higher spleen response rates vs those with delayed initiation.

Testicular Cancer Awareness Month: Early Detection and Risk Assessment Pave the Way Toward Optimal Outcomes

April 30th 2025

Jax DiEugenio

Adam Calaway, MD, MPH, highlights the need for early detection and education in testicular cancer.

Cancer Vaccines Begin to Take Center Stage With Investigators Anticipating an Even Brighter Future

April 30th 2025

Kyle Doherty

Expert investigators discuss the current and future landscape of cancer vaccine development in various tumor types.

Expert Insights and Best Practices in Diagnosing Resectable Early-Stage NSCLC

April 30th 2025

Vamsidhar Velcheti, MD

Panelists discuss how a multidisciplinary approach enhances the early diagnosis of non–small cell lung cancer (NSCLC) by integrating insights from oncology, radiology, pathology, and surgery.

Dr Loong on the Efficacy of D3S-001 in KRAS G12C Inhibitor–Resistant NSCLC

April 30th 2025

Herbert H F Loong, MBBS, PDipMDPath, MRCP, FRCP Edin, FHKCP, FHKAM(Medicine), FASCO

Herbert H F Loong, MBBS(HK), PDipMDPath(HK), MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine), FASCO, discusses the efficacy of D3S-001 in pretreated NSCLC.

Avutometinib/Abemaciclib/Fulvestrant Combo Is Active, Safe in CDK4/6 Inhibitor–Resistant HR+/HER2– Metastatic Breast Cancer

April 29th 2025

Jax DiEugenio

Avutometinib plus abemaciclib and fulvestrant had manageable toxicity in CDK4/6-resistant, HR+/HER2– metastatic breast cancer.

SYN818 Shows Favorable Safety Profile in Locally Advanced or Metastatic Solid Tumors

April 29th 2025

Kristi Rosa

A phase 1b trial examining SYN818 plus olaparib in patients with solid tumors will be conducted in the second half of 2025.

Runimotamab Plus Trastuzumab Is Active and Tolerable in HER2+ Breast Cancer

April 29th 2025

Tony Berberabe, MPH

Runimotamab in combination with trastuzumab led to clinical activity and tolerability vs runimotamab alone in HER2-positive breast cancer.

Dr Sobh on the Effects of NSD2 Overexpression in Multiple Myeloma

April 29th 2025

Amin Sobh, PhD

Amin Sobh, PhD, discusses findings from a study investigating the immune surveillance–modulating capabilities of NSD2 overexpression in multiple myeloma.

Invikafusp Alfa Generates Clinical Activity in Checkpoint Inhibitor–Resistant Solid Tumors

April 29th 2025

Jason Broderick

Invikafusp alfa was active in unresectable, locally advanced or metastatic solid tumors resistant to immune checkpoint inhibitors.

Sequencing Regorafenib After Fruquintinib Improves OS in mCRC

April 29th 2025

Kyle Doherty

Initial fruquintinib followed by regorafenib extended OS vs the reverse sequence of the agents in patients with metastatic colorectal cancer.

See All News